Market Access
Solution Spotlight: Acumetis Model Builder
Sponsored

Solution Spotlight: Acumetis Model Builder

Acumetis Model Builder is a web-based platform that generates complete, formula-linked Excel cost-effectiveness and budget impact models in minutes.

Articles
Executive perspectives: Dr Roch Doliveux

Executive perspectives: Dr Roch Doliveux

As the pharma industry increasingly talks about being patient focussed, Paul Tunnah finds out what this specifically means for Dr Roch Doliveux as he steers a new course for UCB. The man at the helm of biopharmaceutical company UCB is in an ebullient mood following the release of the company’s full year 2012 results. Revenue growth of…

Articles
Executive perspectives: John Castellani

Executive perspectives: John Castellani

With the US pharma market also feeling the winds of change, Paul Tunnah speaks with PhRMA CEO John Castellani to hear his views on the future for the industry. As one of the most influential figures in pharma it is notable that Castellani is a relative newcomer to the sector, having taken the lead role at The Pharmaceutical Research…

Articles
China – a huge opportunity but where to start?

China – a huge opportunity but where to start?

Flic Gabbay explores the pharmaceutical business opportunities in China in our R&D innovation focus month. “Everybody knows they must be in China – but few know why they must be in China,” Dr Jingwu Zang, Senior Vice...

Sales & Marketing

Sales & Marketing
Solution Spotlight: BrandPRO Biopharma
Sponsored

Solution Spotlight: BrandPRO Biopharma

Strong strategy on paper can unravel when priorities collide. BrandPRO Biopharma gives pharmaceutical teams a place to put their decisions to the test

Digital

Market Access

Market Access
Solution Spotlight: Acumetis Model Builder
Sponsored

Solution Spotlight: Acumetis Model Builder

Acumetis Model Builder is a web-based platform that generates complete, formula-linked Excel cost-effectiveness and budget impact models in minutes.

Newsletters and Deep Dive
digital magazine

Oncology

Patients

R&D